RxDoctor Payments DataLook up a doctor →

Victor Ankoma-Sey, MD

Gastroenterology · Houston, TXNPI 1144226515

Payments from drug & device makers

$932,682in general payments, 2019–2025

Across 1,271 payments — averaging $733.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$153K
  • AbbVie$148K
  • Bausch Health US, LLC$131K
  • GSK$127K
  • Intercept Pharmaceuticals, Inc.$106K
  • Genentech, Inc.$75K
  • plus $192K from 44 others
$5,726in research payments, 2019–2025

Across 1 payment — averaging $5726.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch Health US, LLC$6K

What the payments were for

  • Consulting fees$16,2205%
  • Speaking & faculty fees$268,51179%
  • Travel & lodging$25,7858%
  • Food & beverage$29,6569%
  • Education$2020%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$932,682 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$294,281
Medicare patients
511
Services billed
2,700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin226$788,771
VemlidyTenofovir Alafenamide222$369,766
OcalivaObeticholic Acid29$251,504
Ursodiol230$49,288
LinzessLinaclotide27$29,467
Lactulose100$6,333
Tenofovir Disoproxil Fumarate48$6,139
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)11$5,753
ClenpiqSod Picosulf/Mag Ox/Citric Ac20$3,522
Mycophenolate Mofetil23$3,306
Azathioprine65$3,169
Tacrolimus22$3,111
Pantoprazole Sodium149$2,887
ConstuloseLactulose35$2,210
Omeprazole65$1,773

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$11,240$788,771226 claims
GileadVemlidy$152,524$369,766222 claims
Intercept Pharmaceuticals, Inc.Ocaliva$106,244$251,50429 claims
AbbVieLinzess$148,433$29,46727 claims
Ferring Pharmaceuticals Inc.Clenpiq$114$3,52220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →